1 |
Ng SC.Emerging leadership lecture: inflammatory bowel disease in Asia: emergence of a " Western" disease[J]. J Gastroenterol Hepatol, 2015, 30(3): 440-445.
|
2 |
Furfaro F, Bezzio C, Ardizzone S, et al.Overview of biological therapy in ulcerative colitis: current and future directions[J]. J Gastrointestin Liver Dis, 2015, 24(2): 203-213.
|
3 |
Sales-Campos H, Basso PJ, Alves VB, et al.Classical and recent advances in the treatment of infl ammatorybowel diseases[J]. Braz J Med Biol Res, 2015, 48(2): 96-107.
|
4 |
Turner D, Walsh CM, Steinhart AH, et al.Response to cortico-steroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression[J]. Clin Gastroenterol Hepatol, 2007, 5(1): 103-110.
|
5 |
Engel MA, Neurath MF.New pathophysiological insights and modern treatment of IBD[J]. J Gastroenterol, 2010, 45(6): 571-583.
|
6 |
Regueiro M, Loftus EV Jr, Steinhart AH, et al.Medical manage-ment of left-sided ulcerative colitis and ulcerative proctitis: critical evalu-ation of therapeutic trials[J]. Inflamm Bowel Dis, 2006, 12(10): 979-994.
|
7 |
Danese S, Siegel CA, Peyrin-Biroulet L. Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis[J]. Aliment Pharmacol Ther, 2014, 39(10): 1095-1103.
|
8 |
Leblanc S, Allez M, Seksik P, et al.GETAID.Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis[J]. Am J Gastroenterol, 2011, 106(4): 771-777.
|
9 |
Feuerstein JD, Cheifetz AS.Ulcerative colitis: epidemiology, diagnosis, and management[J]. Mayo Clin Proc, 2014, 89(11): 1553-1163.
|
10 |
Marteau P, Probert CS, Lindgren S, et al.Combined oral and enema treatment with Pentasa(mesalazine)is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study[J]. Gut, 2005, 54(7): 960-965.
|
11 |
Safdi M, DeMicco M, Sninsky C, et al.A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis[J]. Am J Gastroenterol, 1997, 92(10): 1867-1871.
|
12 |
Hanauer S, Good LI, Goodman MW, et al.Long-term use of mesalamine(Rowasa)suppositories in remission maintenance of ulcerative proctitis[J]. Am J Gastroenterol, 2000, 95(7): 1749-1754.
|
13 |
D′Albasio G, Pacini F, Camarri E, et al.Combined therapy with 5-ami-nosalicylic acid tablets and enemas for maintaining remission in ulcer-ative colitis: a randomized double-blind study[J]. Am J Gastroenterol, 1997, 92(7): 1143-1147.
|
14 |
Ford AC, Bernstein CN, Khan KJ, et al.Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4): 590-599.
|
15 |
刘敏纹,韩玮等.重度溃疡性结肠炎糖皮质激素治疗反应及其影响因素分析[J].安徽医科大学学报,2014,49(5): 648-652.
|
16 |
Khan KJ, Dubinsky MC, Ford AC, et al.Efficacy of immunosuppressive therapy for inflammatory bowel dis-ease: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4): 630-642.
|
17 |
Ford AC, Sandborn WJ, Khan KJ, et al.Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4): 644-659.
|
18 |
Kornbluth A, Sachar DB.Practice Parameters Committee of the Ameri-can College of Gastroenterology.Ulcerative colitis practice guidelines in adults[J]. Am J Gastroenterol, 2010, 105(3): 501-523.
|